ANVS - InvestorNewsBreaks - Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer's Study at AAIC 2024
Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), will be presenting results from its latest Alzheimer’s study at the Alzheimer’s Association International Conference(R) 2024 (“AAIC”). The conference is slated to run from July 28–Aug. 1, 2024, in Philadelphia as well as online. According to the announcement, Annovis Bio senior VP of research & development Dr. Cheng Fang will present an extended 45-minute session at the conference; the presentation is scheduled to begin at 8 a.m. on July 31. He will be joined by Kathleen A. Welsh-Bohmer, PhD, a professor in psychiatry and neurology at Duke University, and Maria L. Maccecchini, PhD, Annovis Bio founder and president. Titled “Data from Phase 2/3 Clinical Study in Mild to Moderate Alzheimer's Disease,” the presentation will include an overview of significant findings from the company’s recent studies of Buntanetap in patients with mild AD as well an in-depth look at the drug's efficacy and safety in both APOE4 carriers and noncarriers. A premier global forum for the latest advancements in dementia research, AAIC gathers together scientists from around the world to share their findings, discuss new ideas and foster collaborations. “We look forward to sharing the details of our phase 2/3 results with the scientific community at this prominent conference,” said Annovis Bio senior VP of research & development Dr. Cheng Fang in the press release. “We are also grateful for the 45-minute format, which allows us to present our data comprehensively.”
To view the full press release, visit https://ibn.fm/XL4Cm
About Annovis Bio Inc.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information about the company, visit www.AnnovisBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN